• Revue médicale suisse · May 2013

    [Antibody-drug conjugates: a new therapeutic class?].

    • Isabel Chofflon, Pierre-Yves Dietrich, and Nhu-Nam Tran Thang.
    • Service d'oncologie, Département des spécialités de médecine, HUG, 1211 Genève 14. Isabel.ChoffIon@hcuge.ch
    • Rev Med Suisse. 2013 May 22; 9 (387): 1080-2, 1084-6.

    AbstractAntibody-drug conjugates (ADCs) are therapeutic agents combining the specificity of a monoclonal antibody for a target antigen with the delivery of a highly potent cytotoxic drug. Their development has been hampered by numerous problems, which are now better identified and partially solved. This finally led to the recent approval of brentuximab vedotin by the US Food and Drug Administration (FDA), as well as in Europe. Trastuzumab emtasin has also been very recently approved by the FDA. Over 20 other ADCs are being investigated, with two of them (inotuzumab ozogamicin and gemtuzumab ozogamicin) in late stage of clinical evaluation. In the near future, ADCs may provide a powerful and selective treatment option for cancer patient.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…